Protagonist Therapeutics

Protagonist Therapeutics

Protagonist Therapeutics

Protagonist Therapeutics develops orally-stable peptides to treat diseases thatare currently addressed by injectable antibodies.
Founded
2001
Raised
$85M
Follow us
Alexa global traffic share
Latest funding Show all
$22,000,000
Post-IPO equity - 2018
BVF Partners L.P.
$40,000,000
Venture capital (Series C) - 2015
Foresite Capital RA Capital Management Starfish Ventures +4
Team Size
1–10
Employees
Location
Headquarters
$22,000,000 Post-IPO equity
FinSMEs

Protagonist Therapeutics Secures $22M in Equity Financing

Health
$40,000,000 Venture capital (Series C)
Xconomy

Protagonist Nabs $40M, Eyes 1st Trial Of Oral Peptide In Gut Disease

Health Funding